BioSpace News Archive

Drug Development

After Disappointing Study Results, Denali and Sanofi Shift Resources to a Different Alzheimer’s Drug

Denali Therapeutics and its development partner Sanofi announced data from its Phase Ib trial of DNL747 in Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).

June 10, 2020
·
3 min read
·
Mark Terry
BioSpace Global Roundup, June 11

Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

June 10, 2020
·
6 min read
·
Alex Keown
FUJIFILM to Invest $928M in Denmark Biotech Development Site

With this capital investment, the site will be able to double its current drug substance manufacturing capacity and enhance its existing assembly operations. Production lines for bulk drug substance will be expanded, and development will begin on a new fill/finish production line.

June 10, 2020
·
3 min read
·
Krystle Vermes
Helsinn Group supports Conquer Cancer, the ASCO Foundation’s COVID Impacts Cancer fund

Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, announces that Helsinn is supporting Conquer Cancer, the ASCO Foundation’s COVID Impacts Cancer fund, with a donation of US$100,000.

June 10, 2020
·
3 min read
Drug Development

Past Vaccine Failures May Reduce COVID-19 Vaccination Rates

With more than 130 COVID-19 vaccines in development around the world, many of them are bound to fail. When they do, will that erode the public trust in the vaccines that are approved? The answer largely depends on where in the development cycle the vaccines fail and the scope of their failure.

June 10, 2020
·
4 min read
·
Gail Dutton
Business

AbbVie Plunks Down $750 Million Upfront for Cancer Therapy Deal with Genmab

The collaboration will focus on the development of three of Genmab’s bispecific antibodies and will also involve a discovery research collaboration for future antibody therapeutics for cancer.

June 10, 2020
·
3 min read
·
Alex Keown
Drug Development

Mirum CFO Discusses the Road to Potential FDA Approval for Investigational ALGS Treatment

Mirum Pharmaceuticals entered 2020 with a significant bounce after the U.S. Food and Drug Administration turned an end-of-phase meeting into a pre-New Drug Application meeting for its lead asset, maralixibat, an investigational treatment being evaluated for pediatric patients with Alagille syndrome.

June 10, 2020
·
3 min read
·
Alex Keown
Policy

Harvard Professor Indicted Over Failure to Disclose Research Ties to China

Charles Lieber, the former chair of Harvard University’s Chemical Biology Department, was indicted by a federal grand jury this week on two counts of making false statements.

June 10, 2020
·
2 min read
·
Alex Keown
Drug Development

Merck’s Keytruda Fails to Hit Mark in First-Line Bladder Cancer Treatment Trial

KEYNOTE-361 is evaluating Keytruda alone and in combination with chemotherapy compared to chemotherapy alone, the current standard of care, for first-line treatment of advanced or metastatic urothelial carcinoma.

June 10, 2020
·
3 min read
·
Mark Terry
Drug Development

Biopharma Update on the Novel Coronavirus: June 10

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 10, 2020.

June 10, 2020
·
4 min read
·
BioSpace Editorial Staff